Mark Kirschbaum
2020
In 2020, Mark Kirschbaum earned a total compensation of $454.1K as Senior Vice President and Chief Medical Officer at Cyclacel Pharmaceuticals.
Compensation breakdown
| Option Awards | $380,400 |
|---|---|
| Salary | $66,288 |
| Other | $7,447 |
| Total | $454,135 |
Kirschbaum received $380.4K in option awards, accounting for 84% of the total pay in 2020.
Kirschbaum also received $66.3K in salary and $7.4K in other compensation.
Rankings
In 2020, Mark Kirschbaum's compensation ranked 11,271st out of 13,090 executives tracked by ExecPay. In other words, Kirschbaum earned more than 13.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,271 out of 13,090 | 14th |
Division Manufacturing | 4,825 out of 5,618 | 14th |
Major group Chemicals And Allied Products | 1,999 out of 2,251 | 11th |
Industry group Drugs | 1,744 out of 1,951 | 11th |
Industry Pharmaceutical Preparations | 1,290 out of 1,456 | 11th |
Source: SEC filing on April 29, 2021.
Kirschbaum's colleagues
We found two more compensation records of executives who worked with Mark Kirschbaum at Cyclacel Pharmaceuticals in 2020.
News
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2023 pay slips 13% to $661K
May 7, 2024
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2022 pay falls 43% to $764K
April 28, 2023
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2021 pay slips 5% to $1.3M
April 26, 2022
Cyclacel Pharmaceuticals CEO Spiro Rombotis' 2020 pay jumps 39% to $1.4M
April 29, 2021